Study Suggests CBD May Have Antipsychotic Effect in High-Risk Individuals

The psychiatric research journal JAMA Psychiatry has just published a new study suggesting CBD might have antipsychotic effects in individuals at clinical high risk of psychosis. Compelling research demonstrating CBD ’ s therapeutic consequences is built off by the analysis.

Psychiatrists Explore the Underlying Causes for CBD’s Therapeutic Effects

What are the neurocognitive mechanisms that underlie the putative effects of cannabidiol in psychosis? To put it differently, does CBD really help treat psychosis? And if so, how?

Researchers began with the assumption that cannabidiol (CBD) has antipsychotic effects in people. How it has that impact on the brain isn’t completely understood.  Psychiatrists study the chemical reactions that lead to or stem from states that are irregular. For this study, researchers wanted to try and isolate the specific chemical alterations that provide its antipsychotic and therapeutic effects to CBD.

To accomplish this, the study analyzed the effects of CBD in 33 people at clinical high risk (CHR) of psychosis. Past studies have identified the regions in the brain that become perturbed in people and at CHR. Hence the JAMA study had a hypothesis: maybe CBD attenuates, or lessens, those disturbances in the parts of the brain related to psychosis.

Study’s Findings Confirm CBD’s Influence on Brain Regions Implicated in Psychosis

The analysis ’s 33 CHR participants were part of a randomized clinical trial with 19 healthy control individuals. Some participants received a single, 600 mg dose of cannabidiol; no CBD others or a placebo. Researchers analyzed how the CBD affected medial cortex the striatum and midbrain –the target brain regions.

The analysis revealed that activation that was modulated was experienced by all three brain regions . While participants performed a learning task, using an MRI, researchers measured brain activation alongside high risk patients who received a placebo, and control individuals who took no CBD. What they discovered was that CHR patients who took CBD had activation levels about in the middle between healthy people with no disturbances and CHR patients who took no CBD.

In a nutshell, CBD did have the attenuating effects researchers had hypothesized. Dysfunction was helped by the oral dose of cannabidiol in all three brain regions. And that means the study may have identified one of the mechanisms responsible for CBD’s therapeutic benefits.

While the analysis ’s findings have implications for psychiatric medication and treating people at high risk for psychosis, it has significance for anyone interested in the effects of cannabis on mental health.

There are studies that have drawn on links between regular and frequent cannabis use and the development of psychosis. Others have linked psychosis with modifications to the endocannabinoid system, whether cannabinoid-stimulated or not. At exactly the same time, research shows CBD, a non-psychoactive cannabinoid, has an almost opposite neural and behavioral impact into THC. With this latest study, scientists know more about why this is.

Posted in: News

Comments are closed.